Unified AI-Powered Platform Improving Patient Access Reducing Provider Burnout with Aniq Rahman Fabric TRANSCRIPT
Release Date: 08/05/2025
Developing Immunotherapy to Fight Bone Cancer with Paul Romness and Olivia Egge OS Therapies TRANSCRIPT
Empowered Patient Podcast
Paul Romness, Chairman, CEO, and President of OS Therapies, and Olivia Egge, a member of the Board of Directors of OS Therapies, discuss osteosarcoma, a rare and aggressive form of bone cancer that primarily affects teenagers. OS Therapies is developing an immunotherapy that utilizes a weakened form of the listeria bacteria to stimulate the immune system and prevent the spread of cancer cells to the lungs and brain. Olivia's experience as a patient has motivated her to advocate for better treatment options and join the board of OS Therapeutics. Paul explains, "So osteosarcoma is quite...
info_outline
Developing Immunotherapy to Fight Bone Cancer with Paul Romness and Olivia Egge OS Therapies
Empowered Patient Podcast
Paul Romness, Chairman, CEO, and President of OS Therapies, and Olivia Egge, a member of the Board of Directors of OS Therapies, discuss osteosarcoma, a rare and aggressive form of bone cancer that primarily affects teenagers. OS Therapies is developing an immunotherapy that utilizes a weakened form of the listeria bacteria to stimulate the immune system and prevent the spread of cancer cells to the lungs and brain. Olivia's experience as a patient has motivated her to advocate for better treatment options and join the board of OS Therapeutics. Paul explains, "So osteosarcoma is quite...
info_outline
New Inhibitor Drug Transforms Cancer Treatment Accessibility with Dan Schmitt Actuate Therapeutics TRANSCRIPT
Empowered Patient Podcast
Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option. Dan explains, "So, GSK-3β is a known...
info_outline
New Inhibitor Drug Transforms Cancer Treatment Accessibility with Dan Schmitt Actuate Therapeutics
Empowered Patient Podcast
Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option. Dan explains, "So, GSK-3β is a known...
info_outline
Democratizing Molecular Diagnostics Transforming Transplant Success with Andrea James iMDx TRANSCRIPT
Empowered Patient Podcast
Andrea James, Chief Financial Officer at iMDx, is focused on expanding access to innovative molecular diagnostic testing staring with a test for monitoring transplanted organ health. The test measures the donor-derived cell-free DNA which can indicate the need for drugs to target organ rejection before invasive procedures are required. The company is developing a kit-based version of the test that can be run by hospitals rather than relying on centralized labs, to increase access to this diagnostic and improve transplant outcomes. Andrea explains, "We changed our name on June 17th from...
info_outline
Democratizing Molecular Diagnostics Transforming Transplant Success with Andrea James iMDx
Empowered Patient Podcast
Andrea James, Chief Financial Officer at iMDx, is focused on expanding access to innovative molecular diagnostic testing staring with a test for monitoring transplanted organ health. The test measures the donor-derived cell-free DNA which can indicate the need for drugs to target organ rejection before invasive procedures are required. The company is developing a kit-based version of the test that can be run by hospitals rather than relying on centralized labs, to increase access to this diagnostic and improve transplant outcomes. Andrea explains, "We changed our name on June 17th from...
info_outline
Healthcare Financial Recovery Driven by Focus on People First with James Hereford Fairview Health Services TRANSCRIPT
Empowered Patient Podcast
James Hereford, President and CEO of Fairview Health Services, describes this Minnesota-based healthcare system's $600 million turnaround and the importance of focusing on people and processes, not just technology changes. Addressing staff shortages, quality of care, and patient experience led to finding a holistic approach that improved financial outcomes and changed the culture in a sustainable way. Investments have been made in community programs like food access and vaccination events, recognizing the impact of social determinants of health on patient outcomes. James explains, "When doing...
info_outline
Healthcare Financial Recovery Driven by Focus on People First with James Hereford Fairview Health Services
Empowered Patient Podcast
James Hereford, President and CEO of Fairview Health Services, describes this Minnesota-based healthcare system's $600 million turnaround and the importance of focusing on people and processes, not just technology changes. Addressing staff shortages, quality of care, and patient experience led to finding a holistic approach that improved financial outcomes and changed the culture in a sustainable way. Investments have been made in community programs like food access and vaccination events, recognizing the impact of social determinants of health on patient outcomes. James explains, "When doing...
info_outline
Innovative Homeostasis Focused Drugs to Treat Root Causes of Disease with Steve Butts Arrivo BioVentures TRANSCRIPT
Empowered Patient Podcast
teve Butts, Co-Founder and CEO of Arrivo BioVentures, is a biopharmaceutical company focused on developing therapies that target the root causes of disease rather than just treating the symptoms. Their drugs treat major depressive disorder and acute pancreatitis through novel epigenetic mechanisms of action. Sex-based differences were observed in clinical trials where the drug SP-624 showed efficacy in females but not in males, which could lead to a paradigm shift in how depression is treated in men and women. Steve explains, "We've evolved over time at Arrivo and with our previous companies....
info_outline
Innovative Homeostasis Focused Drugs to Treat Root Causes of Disease with Steve Butts Arrivo BioVentures
Empowered Patient Podcast
Steve Butts, Co-Founder and CEO of Arrivo BioVentures, is a biopharmaceutical company focused on developing therapies that target the root causes of disease rather than just treating the symptoms. Their drugs treat major depressive disorder and acute pancreatitis through novel epigenetic mechanisms of action. Sex-based differences were observed in clinical trials where the drug SP-624 showed efficacy in females but not in males, which could lead to a paradigm shift in how depression is treated in men and women. Steve explains, "We've evolved over time at Arrivo and with our previous...
info_outlineAniq Rahman, Founder and CEO of Fabric, a technology company that uses an AI-powered platform to support health systems, health plans, and employers, to streamline patient care, scheduling appointments, and receiving virtual care. The system can triage patients, route them to appropriate care, and simplify the provider workflows to improve operational efficiency, drive better patient outcomes, and reduce provider burnout. Fabric is taking an integrated approach to healthcare technology rather than offering individual point solutions in order to create a seamless experience for patients and providers.
Aniq explains, "We started Fabric about four years ago now in 2021 in the midst of the pandemic. And we're a technology company fundamentally. So, Fabric builds technology. We work primarily with health systems, but also with health plans and employers, to really help bring together the care journey of a patient. So that's everything from helping a patient find care, triage their symptoms, get virtual care, and also help with things like scheduling appointments and follow-ups. So we've built really an end-to-end platform today that has AI at its core and is able to sort of route patients more appropriately and then also help improve the workflows of providers and create efficiency on the clinical side as well."
"Yes, so one of the things that has been sort of core to the Fabric vision is figuring out ways to actually improve patient experience, provider experience, and operational throughput without it compromising any of those three buckets. And so one of the things that we've been fortunate to have is a virtual care platform that we actually acquired. We bought a company called Zipnosis back in 2023, and Zipnosis had built a pretty robust set of clinical protocols to help streamline the virtual urgent care visits effectively. So, say a patient's coming in with something like a pink eye or a urinary tract infection, or even just a cold or flu, we have protocols that allow patients to go through and answer a series of questions in an adaptive interview. And based on the patient responses, we can figure out if that patient needs to be seen in person or may need to get referred out to the emergency department."
#FabricHealth #MedAI #AI #DigitalAssistant #DigitalHealth #TriageEvaluation
